Weiming Li

Novel BCR-ABL1 Tyrosine Kinase Inhibitor (TKI) HQP1351 (Olverembatinib) Is Efficacious and Well Tolerated in Patients with T315I-Mutated Chronic Myeloid Leukemia (CML): Results of Pivotal (Phase II) Trials

Qian Jiang, Xiao‐Jun Huang, Zi Chen et al. · Blood · 2020 · 27 citations

Medicine, Oncology, Pharmacology +8

The Effect of the COVID-19 Vaccine on Daily Cases and Deaths Based on Global Vaccine Data

Zhiwei Li, Xiangtong Liu, Mengyang Liu et al. · Vaccines · 2021 · 19 citations · Full text

Veterinary Medicine, Infectious Disease Control, Infectious Diseases +12

Comparison of outcomes of idarubicin intensified TBI–CY and traditional TBI–CY conditioning regimen for high-risk acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation: A single center experience

Qiuling Wu, Ran Zhang, Huafang Wang et al. · Leukemia Research · 2015 · 14 citations

Medicine, Oncology, Chemotherapy +15

A Novel Risk Predictive Scoring Model for Predicting Subsequent Infection After Carbapenem-Resistant Gram-Negative Bacteria Colonization in Hematological Malignancy Patients

Qiuling Wu, Chenjing Qian, Hua Yin et al. · Frontiers in Oncology · 2022 · 11 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +17

Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP) with T315I Mutation

Qian Jiang, Zongru Li, Yue Hou et al. · Blood · 2022 · 11 citations

Medicine, Oncology, Pharmacology +12